Literature DB >> 2292525

The pharmacokinetics of the oral cephalosporins--a review.

R Wise1.   

Abstract

The pharmacokinetics of the older and more recent oral cephalosporins are reviewed. With the exception of cefadroxil the older agents (cephalexin, cephradine and cefaclor) have serum elimination half-lives of less than or equal to 1 h and hence have to be administered three to four times daily. The urinary recovery of these agents is high (greater than 80% of oral dose) with the exception of cefaclor (54%). Cefaclor is also chemically unstable. The newer agents can be divided into those that are prodrugs (cefpodoxime proxetil and cefuroxime axetil) and compounds that are absorbed as such (cefixime, cefprozil and ceftibuten). They all have half-lives greater than 1.25 h and can be given once or twice daily. The penetration of these agents into an inflammatory exudate was studied and found to be cefixime 132%, ceftibuten 113%, cefpodoxime 104%, cefuroxime 92% and cefprozil 79% of the serum concentration. The penetration of cefpodoxime and cefixime into the respiratory tract was also studied; the mean percentage bronchial mucosal penetration was 52% for the former and 38% for cefixime. The urinary recovery of these newer agents (with the exception of ceftibuten) tends to be less than that of the earlier agents. There was a relationship between the serum elimination half-life of these agents and the degree of tissue penetration, those agents with longer half-lives penetrating to a greater extent.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2292525     DOI: 10.1093/jac/26.suppl_e.13

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  18 in total

1.  Detection of favorable oral cephalosporin-clavulanate interactions by in vitro disk approximation susceptibility testing of extended-spectrum-Beta-lactamase-producing members of the enterobacteriaceae.

Authors:  Jennifer D Campbell; James S Lewis; M Leticia McElmeel; Letitia C Fulcher; James H Jorgensen
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

Review 2.  Clinical and economic considerations in the use of third-generation oral cephalosporins.

Authors:  S T Chambers; D R Murdoch; M J Pearce
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

3.  A study to determine the pharmacokinetics and inflammatory fluid penetration of two doses of a solid formulation of the hexetil prodrug of a trinem, sanfetrinem (GV 104326).

Authors:  R Wise; J M Andrews; L Da Ros; J Child; D Mortiboy
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 4.  Cefpodoxime proxetil in the treatment of lower respiratory tract infections.

Authors:  A M Geddes
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 5.  A review of the pharmacokinetics of cefpodoxime proxetil.

Authors:  M T Borin
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 6.  Cefpodoxime proxetil in upper respiratory tract infections.

Authors:  E Bergogne-Berezin
Journal:  Drugs       Date:  1991       Impact factor: 9.546

7.  Treatment failure definitions for non-purulent skin and soft tissue infections: a systematic review.

Authors:  Krishan Yadav; Avik Nath; Kathryn N Suh; Lindsey Sikora; Debra Eagles
Journal:  Infection       Date:  2019-08-05       Impact factor: 3.553

8.  Comparison of ceftibuten vs. amoxicillin/clavulanic acid as antibiotic prophylaxis in cholecystectomy and/or biliary tract surgery.

Authors:  H Orozco; J Sifuentes-Osornio; C Chan; H Medina-Franco; F Vargas-Vorackova; E Prado; J Arch
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

Review 9.  Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use.

Authors:  G L Kearns; R A Young
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

10.  Shedding of Clostridium difficile, fecal beta-lactamase activity, and gastrointestinal symptoms in 51 volunteers treated with oral cefixime.

Authors:  E Chachaty; C Bourneix; S Renard; M Bonnay; A Andremont
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.